STING agonists have the ability to elicit both innate and adaptive immune responses, producing inflammatory cytokines that can remodel the tumour microenvironment56 which make them good candidates for non-inflamed tumours characterised by the lack of pre-existing TILs. Here, STING1 is linked to neoplasm.